

Date and time: Tuesday 8 October 2013, 1000-1600

Minutes: Confirmed

Guideline Development Group Meeting 3

Place: Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ

Present: John Alexander, Consultant in Paediatrics & Paediatric Intensive Care
Tara Burn, Patient member
Erol Gaillard, Senior Lecturer & Honorary Consultant in Paediatric Respiratory Medicine
Ren Gilmartin, Respiratory Nurse Specialist
Val Hudson, Patient member
Angela Key, Deputy in Respiratory Dept
Melanie McFeeters, Consultant Nurse in Children’s Respiratory Diseases
Andrew Menzies-Gow (Chair), Consultant Respiratory Physician
Michael Thomas, Professor of Primary Care Research & Principal in General Practice
Emily Davies, Research Fellow, NCGC
Elisabetta Fenu, Senior Health Economist, NCGC
Saoussen Ftouh, Senior Research Fellow & Project Manager, NCGC
Alex Haines, Health Economist, NCGC
Bernard Higgins, Clinical Director, NCGC
Rachel O’Mahony, Senior Research Fellow, NCGC
Jill Parnham, Operations Director, NCGC

Apologies: Matthew Masoli, Consultant Respiratory Physician
Georgina Russell, Clinical Fellow, Royal College of Physicians
Tahmina Siddiqui, General Practitioner
Paul Miller, Senior Information Scientist, NCGC

In attendance:

NICE Staff:		
NICE attendee 1	Caroline Keir, Guidelines Commissioning Manager	

Observers:

--	--	--

Notes

Notes

1. **Welcome and declarations of interest.** The Chair welcomed the group to the third meeting of this GDG. Apologies were received from MM and TS. The Chair reviewed and requested updates to the declarations of interest register. AMG declared a personal pecuniary interest: he has received payment for attending an advisory board for Amgen who are trialling a novel monoclonal antibody for use in severe asthma. The GDG agreed that this did not represent a conflict of interest therefore no action was required. No other declarations were received from GDG members and therefore no further action was required.
2. **GDG2 minutes.** The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.
3. **Review linking evidence to recommendations:** The GDG reviewed the linking evidence to recommendations for serum IgE.
4. **Evidence review:** The GDG reviewed the clinical and cost effectiveness evidence for eosinophils.
5. **Evidence review:** The GDG reviewed the clinical and cost effectiveness evidence for occupational asthma.
6. **Protocols:** The GDG reviewed and agreed 4 protocols.
7. **Any other business:** None.

Date, time and venue of the next meeting

Tuesday 19 November 2013, 1000-1600 at NCGC, 180 Great Portland Street, London W1W 5QZ